Anthony Rees is currently Principle at Rees Consulting AB, Uppsala, Sweden. He was lecturer in Molecular Biophysics and Student of Christ Church from 1980 to 1990 at the University of Oxford. From 1990-1997 he was Professor and Head of the School of Biology and Biochemistry, University of Bath where he is an Emeritus Professor and holds an Honorary Doctor of Science. In 1989 he was a scientific cofounder with Graham Richards of Oxford Molecular, which became one of the earliest UK biotechnology companies to be listed on the London Stock Exchange. He has been visiting Professor at the Universities of Montpellier and Lund, scientific director of the French company Synt:em, CEO of the Swedish company MIP Technologies and Chairman of the Board of the antibody technology company, F-star. He is a member of the American Association for the History of Science and has published more than 120 scientific papers, a number of books and is an inventor on more than 30 patents.

The Antibody Molecule is a marvelous synthesis of pertinent scientific literature from the late nineteenth century to the modern day, by someone who has an intimate firsthand knowledge of what it is like to have worked in this field.

• 1. Antibody pre-history: The emergence of empirical immunology ; 2. Pre-molecular immunology: The dawn of mechanism ; 3. Structural chemistry: Locks, keys and colloids ; 4. The foundations of antibody-antigen recognition emerge ; 5. The cellular reformation ; 6. The molecular path unfolds ; 7. Uncovering the origins of antibody diversity ; 8. Immunoglobulin constant regions ; 9. Effector functions of constant regions ; 10. Transmission and catabolism of IgG ; 11. The structural context of antibody diversity ; 12. Monoclonal antibodies and the mechanisms of hypermutation ; 13. Antibody structure prediction and development of humanization strategies ; 14. Antibody engineering: Improving on natural immunity ; 15. Therapeutic antibodies: Case study 1: Prevention of respiratory syncytial virus illness ; 16. Therapeutic antibodies: Case study 2: Targeting breast cancer ; 17. Antibodies: The therapeutic future

Anthony Rees is currently Principle at Rees Consulting AB, Uppsala, Sweden. He was lecturer in Molecular Biophysics and Student of Christ Church from 1980 to 1990 at the University of Oxford. From 1990-1997 he was Professor and Head of the School of Biology and Biochemistry, University of Bath where he is an Emeritus Professor and holds an Honorary Doctor of Science. In 1989 he was a scientific cofounder with Graham Richards of Oxford Molecular, which became one of the earliest UK biotechnology companies to be listed on the London Stock Exchange. He has been visiting Professor at the Universities of Montpellier and Lund, scientific director of the French company Synt:em, CEO of the Swedish company MIP Technologies and Chairman of the Board of the antibody technology company, F-star. He is a member of the American Association for the History of Science and has published more than 120 scientific papers, a number of books and is an inventor on more than 30 patents.

The Antibody Molecule is a marvelous synthesis of pertinent scientific literature from the late nineteenth century to the modern day, by someone who has an intimate firsthand knowledge of what it is like to have worked in this field.

• 1. Antibody pre-history: The emergence of empirical immunology ; 2. Pre-molecular immunology: The dawn of mechanism ; 3. Structural chemistry: Locks, keys and colloids ; 4. The foundations of antibody-antigen recognition emerge ; 5. The cellular reformation ; 6. The molecular path unfolds ; 7. Uncovering the origins of antibody diversity ; 8. Immunoglobulin constant regions ; 9. Effector functions of constant regions ; 10. Transmission and catabolism of IgG ; 11. The structural context of antibody diversity ; 12. Monoclonal antibodies and the mechanisms of hypermutation ; 13. Antibody structure prediction and development of humanization strategies ; 14. Antibody engineering: Improving on natural immunity ; 15. Therapeutic antibodies: Case study 1: Prevention of respiratory syncytial virus illness ; 16. Therapeutic antibodies: Case study 2: Targeting breast cancer ; 17. Antibodies: The therapeutic future

Anthony Rees is currently Principle at Rees Consulting AB, Uppsala, Sweden. He was lecturer in Molecular Biophysics and Student of Christ Church from 1980 to 1990 at the University of Oxford. From 1990-1997 he was Professor and Head of the School of Biology and Biochemistry, University of Bath where he is an Emeritus Professor and holds an Honorary Doctor of Science. In 1989 he was a scientific cofounder with Graham Richards of Oxford Molecular, which became one of the earliest UK biotechnology companies to be listed on the London Stock Exchange. He has been visiting Professor at the Universities of Montpellier and Lund, scientific director of the French company Synt:em, CEO of the Swedish company MIP Technologies and Chairman of the Board of the antibody technology company, F-star. He is a member of the American Association for the History of Science and has published more than 120 scientific papers, a number of books and is an inventor on more than 30 patents.

The Antibody Molecule is a marvelous synthesis of pertinent scientific literature from the late nineteenth century to the modern day, by someone who has an intimate firsthand knowledge of what it is like to have worked in this field.

• 1. Antibody pre-history: The emergence of empirical immunology ; 2. Pre-molecular immunology: The dawn of mechanism ; 3. Structural chemistry: Locks, keys and colloids ; 4. The foundations of antibody-antigen recognition emerge ; 5. The cellular reformation ; 6. The molecular path unfolds ; 7. Uncovering the origins of antibody diversity ; 8. Immunoglobulin constant regions ; 9. Effector functions of constant regions ; 10. Transmission and catabolism of IgG ; 11. The structural context of antibody diversity ; 12. Monoclonal antibodies and the mechanisms of hypermutation ; 13. Antibody structure prediction and development of humanization strategies ; 14. Antibody engineering: Improving on natural immunity ; 15. Therapeutic antibodies: Case study 1: Prevention of respiratory syncytial virus illness ; 16. Therapeutic antibodies: Case study 2: Targeting breast cancer ; 17. Antibodies: The therapeutic future